Rana McKay: Surgical castration allows access to abiraterone to Brazilians with mPC
Rana McKay, Associate Professor of Medicine at UC San Diego, shared a post on X:
“Amazing work lead by Daniel Herchenhorn demonstrating that surgical castration would allow access to abiraterone to 65%+ Brazilians with mPC without increased cost.”
Authors: Fernando Sabino Marques Monteiro, Andre Deeke Sasse, Denizar Vianna Araujo, Rana R. McKay, Karine Martins da Trindade, Andrey Soares, João Ricardo Alves, Douglas Andreas Valverde, Diogo Assed Bastos, Nicholas D. James, Daniel Herchenhorn
More posts featuring Rana McKay.
Dr. Rana McKay is a board-certified medical oncologist and specializes in urogenital cancers, offering treatment for bladder, kidney, prostate, and testicular cancer patients. Leading a multi-disciplinary prostate cancer clinic at UC San Diego, she ensures comprehensive care through collaboration with urologists and radiation oncologists.
As an associate professor, Dr. McKay mentors students and conducts research on clinical trials and novel biomarkers for genitourinary malignancies. Dr. McKay is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023